In this featured collection, we put a spotlight on medication assisted treatment (MAT) for opioid use disorder (OUD). Research has proven that MAT is an evidence-based strategy for treating individuals with OUD; individuals who use MAT as part of their treatment and recovery plan are more likely to be retained in treatment and to have fewer adverse events such as opioid overdose and opioid overdose mortality.
This collection compiles research and implementation materials from the Improving Addiction Care Team (IMPACT) program from Oregon Health & Science University (OHSU). IMPACT is an interprofessional, hospital-based addictions team that provides addiction medicine consults to patients being treated at OHSU who have a substance use disorder (SUD).
The Center for Opioid Research and Education is a consortium of physicians, nurses, pharmacists and patients who together created procedure specific opioid prescribing guidelines. In 2017, the consortium published guidelines offering consensus recommendations for the range of appropriate opioid prescribing following 20 common surgical procedures, and in 2018 published guidelines for 14 common dental procedures.
This four page document presents the highlights from the 2019 National Academies report on medication assisted treatment for opioid use disorder. Funding Source: National Institute on Drug Abuse, National Institutes of Health; Substance Abuse and Mental Health Services Administration, U.S. Department of Health and Human Services
This one page document summarizes the conclusions of the 2019 National Academies report on medications for opioid use disorder.
A brief overview of the emergency department (ED) based induction to buprenorphine program initiated at Yale New Haven Hospital. This report describes a randomized controlled trial that provided patients with opioid use disorder seen in the emergency room with either a substance use disorder screening and referral to treatment, a screening and brief intervention with facilitated referral to treatment, or induction to buprenorphine medicated assisted treatment and a referral to follow up treatment. Those patients offered buprenorphine were significantly more likely to be engaged in treatment 30 days later than the other patients. This model has subsequently been adopted in EDs across the country. This report is part of the Addiction Policy Forum’s Spotlight series which highlights innovative programs to address the opioid crisis.
This article describes the case of an individual prescribed buprenorphine for opioid use disorder (OUD) who did not achieve treatment stability at the maximum dose allowed by the patient’s insurer of 24 mg daily.
This 3 page briefing paper discusses the role legal aid services can play in helping address the impact of the opioid crisis on individuals, families, and communities.
A systematic review prepared for the Agency for Healthcare Research and Quality that evaluated the effectiveness and harms of opioids compared to nonopioid analgesics in the emergency department.
This 2019 review from Oregon’s Drug Use Research & Management Program examined whether removing Medicaid prior authorization requirements for medication assisted treatment for individuals with opioid use